Michael Byrnes insider trades: eFFECTOR Therapeutics (EFTR) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 7, 2022 | EFTR | ↑ Buy | 25,000 | $1.33 | $33K | Direct | Jun 7, 2022 (0d) |
| Mar 28, 2017 | OCRX | ↑ Buy | 3,000 | $1.28 | $4K | Direct | Mar 28, 2017 (0d) |
| Jan 15, 2016 | OCRX | ↑ Buy | 3,500 | $2.07 | $7K | Direct | Jan 19, 2016 (4d) |
| May 6, 2015 | OCRX | ↑ Buy | 2,500 | $3.61 | $9K | Direct | May 6, 2015 (0d) |
| Oct 1, 2014 | OCRX | ↑ Buy | 2,000 | $4.81 | $10K | Direct | Oct 2, 2014 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Michael Byrnes's insider trades
Michael Byrnes is Chief Financial Officer at eFFECTOR Therapeutics (EFTR). Since Oct 1, 2014, Michael has reported 5 open-market purchases worth $63K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (20 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EFTR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.